Sign up to save your podcasts
Or
Share Mar 2021 - Guidelines on the diagnosis and treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Mar 2021 - Guidelines on the diagnosis and treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
JPRAS ARTICLE DISCUSSED:
UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG)
Philip Turton, Dima El-Sharkawi, Iain Lyburn, Bhupinder Sharma, Preethika Mahalingam, Suzanne D. Turner, Fiona MacNeill, Laura Johnson, Stephen Hamilton, Cathy Burton, Nigel Mercer
JPRAS - November 11, 2020
AUTHORS IN ATTENDANCE:
Mr Philip Turton, Dr Dima El-Sharkawi, Professor Iain Lyburn, Professor Suzanne D. Turner, Ms Fiona MacNeill, Dr Cathy Burton, Mr Nigel Mercer
CLASSIC ARTICLE FROM OUR AUTHORS:
Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial
View all episodes
By JPRAS PLASTA ICOPLASTJPRAS ARTICLE DISCUSSED:
UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG)
Philip Turton, Dima El-Sharkawi, Iain Lyburn, Bhupinder Sharma, Preethika Mahalingam, Suzanne D. Turner, Fiona MacNeill, Laura Johnson, Stephen Hamilton, Cathy Burton, Nigel Mercer
JPRAS - November 11, 2020
AUTHORS IN ATTENDANCE:
Mr Philip Turton, Dr Dima El-Sharkawi, Professor Iain Lyburn, Professor Suzanne D. Turner, Ms Fiona MacNeill, Dr Cathy Burton, Mr Nigel Mercer
CLASSIC ARTICLE FROM OUR AUTHORS:
Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial